Abstract
There has been a clear trend towards decreased reliance upon animal studies and increased emphasis upon experiments with human-derived tissues. Nonetheless, we continue to need investigations of interspecies differences for two principal reasons: (1) to prospectively design experiments so that the animal species most similar to humans can be chosen, on a case-by-case basis, for each drug; (2) to properly evaluate and interpret data obtained from the experiments ("risk assessment"). Four core examples derived from the work in our FDA laboratory are used to illustrate these points. For paclitaxel, different metabolites were formed in humans and rats, which makes metabolic drug-drug interaction studies in rats irrelevant. For zidovudine (AZT), rapid glucuronidation in humans produced a much shorter half-life than expected from studies in animals, which have negligible glucuronidation. The toxicology and efficacy of both parent drug and metabolite need to be assessed in cases such as iododeoxydoxorubicin, in which the parent molecule is the dominant circulating species in mice, but patients have more than 10-fold greater exposure to the metabolite compared with the parent. While rats have highly-active arylamine N-acetyltransferase...Continue Reading
References
Mar 21, 1990·Journal of the National Cancer Institute·L GianniG Bonadonna
Jan 1, 1995·Cancer Chemotherapy and Pharmacology·C A Jamis-DowJ M Collins
Mar 24, 1993·JAMA : the Journal of the American Medical Association·C C PeckJ M Collins
Jul 27, 1999·Chemico-biological Interactions·A P Li
Citations
Aug 25, 2011·Journal of Industrial Microbiology & Biotechnology·Sjef CornelissenBruno Bühler
Nov 14, 2002·Biochemical Pharmacology·Lay Beng GohThomas Friedberg
Jul 25, 2003·European Journal of Pharmacology·Jeffery J AndersonMark A Varney
Jul 10, 2012·BMC Medical Ethics·Ray GreekLawrence A Hansen
Apr 5, 2007·Philosophy, Ethics, and Humanities in Medicine : PEHM·Niall Shanks, Rebecca A Pyles
Sep 10, 2010·Philosophy, Ethics, and Humanities in Medicine : PEHM·Ray Greek, Jean Greek
Mar 27, 2010·Arhiv za higijenu rada i toksikologiju·Domagoj DikićNada Orsolić
Jul 30, 2010·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Petra JancovaEva Anzenbacherova
Sep 21, 2006·The Veterinary Clinics of North America. Small Animal Practice·Katrina L Mealey
Apr 1, 2006·Toxicology·Jürgen PauluhnGabriele Leng
Dec 19, 2002·Drug Metabolism Reviews·Shufeng ZhouJames W Paxton
Apr 15, 2015·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·A I Loureiro, P Soares-da-Silva
Sep 18, 2013·Drug Metabolism and Pharmacokinetics·Yoshihiro ShibataMasato Chiba
Feb 3, 2015·European Journal of Pharmacology·Nuno Miguel PiresPatrício Soares-da-Silva
Jul 30, 2005·Toxicology·Jürgen Pauluhn
Apr 5, 2005·Toxicologic Pathology·John R Foster
Sep 10, 2010·Reproductive Sciences·Kristel Van CalsterenFrédéric Amant
Dec 1, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Alan F HofmannGeny M M Groothuis
May 12, 2010·Nature Biotechnology·William B MattesRaymond L Woosley
Apr 11, 2019·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Elizabeth A HausnerXi Yang
Feb 2, 2011·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Tsuneo DeguchiTakashi Izumi
Apr 19, 2015·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Nathalie RiouxNigel J Waters
Feb 25, 2003·Toxicologic Pathology·Jay Tibbitts
Jan 1, 2012·Personalized Medicine·Ray GreekMark J Rice